{
    "nct_id": "NCT06560632",
    "official_title": "Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-3467 Alone and in Combination with Olaparib in Participants with Advanced Solid Tumors (POLAR Trial)",
    "inclusion_criteria": "* Male or female participants ≥18 years of age at the time of signing the informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participant must have one of the following that has progressed or was non-responsive to prior systemic therapy and for which no standard or available known therapeutic option exists:\n\n  1. locally advanced or metastatic epithelial ovarian cancer (including fallopian tube or primary peritoneal), or\n  2. metastatic breast cancer, or\n  3. metastatic castration-resistant prostate cancer (mCRPC), or\n  4. pancreatic adenocarcinoma\n* Measurable disease per RECIST v1.1 (exceptions for participants with non-measurable but evaluable disease [per RECIST and or PSA/CA-125])\n* Next generation sequencing (NGS) report demonstrating eligible tumor biomarker\n* Provision of archival tumor tissue, or if adequate archival tumor tissue is not available, provision of a fresh biopsy if there is a lesion that can be safely biopsied\n* Acceptable organ function at Screening\n* Acceptable hematologic function at Screening\n* Life expectancy ≥12 weeks after the start of the treatment according to the Investigator's judgment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.\n* Uncontrolled, symptomatic brain metastases.\n* Presence of other known active invasive cancers\n* History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis\n* Prior therapy with a Polθ inhibitor other than RP-3467",
    "miscellaneous_criteria": ""
}